Zeeshan Syedain

Zeeshan Syedain


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2017 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
ZSZeeshan Syedain
Zeeshan Syedain
Melanie L. GrahamMelanie L. Graham
Melanie L. Graham
TDTy B. Dunn
Ty B. Dunn
TOTimothy O’brien
Timothy O’brien
SJSandra L. Johnson
Sandra L. Johnson
RTRobert T. Tranquillo
Robert T. Tranquillo
A decellularized tissue tube grown from human skin cells and fibrin becomes repopulated by recipient cells when tested in baboons as a vascular graft for hemodialysis access.

17 March 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
ZSZeeshan Syedain
Zeeshan Syedain
BHBee Haynie
Bee Haynie
SJSandra L. Johnson
Sandra L. Johnson
MLMatthew Lahti
Matthew Lahti
JBJames Berry
James Berry
RTRobert T. Tranquillo
Robert T. Tranquillo
A pulmonary replacement valve made from three tubes of cell-derived matrix functioned for 52 weeks in lambs and calcified less than commercial valves.

9 March 2023 in The Journal of Vascular Access
Verified
Journal Article
Closed access
AEAdrian Ebner
Adrian Ebner
SGSantiago Gallo
Santiago Gallo
JCJuan Castellano
Juan Castellano
MFMaria Filartiga
Maria Filartiga
AHAllie Haarstad
Allie Haarstad
HWHaimanot Wasse
Haimanot Wasse
Introduction: The long-term survival and low complication rate of autogenous fistulas for hemodialysis access is often offset by early thrombosis and slow or failed maturation leading to the use of central venous catheters. A regenerative material may have the potential to overcome these limitations. A completely biological acellular vascular conduit was investigated in this first-in-human clinical study. Methods: With approval of the ethics board and patients’ informed consent, five subjects were enrolled based on predetermined inclusion criteria. Five patients underwent implant of a novel acellular, biological tissue conduit (TRUE AVC™) in the upper arm in a curved configuration between brachial artery and axillary vein. After maturation, standard dialysis was commenced through the new access. Patients were followed up to 26 weeks with ultrasound and physical exam. Serum samples were evaluated for an immune response to the novel allogeneic human tissue implant. Results: This new tissue conduit handled well surgically, with properties similar to that of native human vein. Post procedure conduit flow was excellent in all cases, averaging 1098 ± 388 ml/min at week 4 and remaining stable through 1248 ± 355 ml/min at 26 weeks. Surgical site healing was normal with no edema or erythema by week 4. Six-month primary assisted patency was 80% and secondary patency was 100%. Prescribed dialysis was successfully delivered without infection, and there was no significant change in conduit diameter. Serum testing showed no increase in PRA or IgG specific to the TRUE AVC. One implant required intervention at 5 months with thrombectomy and covered stent procedure. Conclusion: This first-in-human 6-month study with favorable patency and low complication rate establishes the initial safety and feasibility of this novel biological tissue conduit for dialysis access in patients with end-stage kidney disease. Its mechanical durability and lack of immune response establishes TRUE AVC as a potential regenerative material for clinical use.

16 April 2021 in Journal of the Mechanical Behavior of Biomedical Materials
Verified
Journal Article
Closed access
ZSZeeshan Syedain
Zeeshan Syedain
APAbrielle Prunty
Abrielle Prunty
JLJirong Li
Jirong Li
RTRobert T. Tranquillo
Robert T. Tranquillo

16 October 2024 in Communications Medicine
Verified
Journal Article
Open access
PDF file
ZSZeeshan Syedain
Zeeshan Syedain
MLMatthew Lahti
Matthew Lahti
GHGurumurthy Hiremath
Gurumurthy Hiremath
JBJames Berry
James Berry
JCJohn P. Carney
John P. Carney
RTRobert T. Tranquillo
Robert T. Tranquillo
Background Growth is the holy grail of tissue implants in pediatrics. No vascular graft currently in use for surgical repairs of congenital heart defects has somatic growth capacity. Methods Biologically-engineered grafts (6 mm) grown from donor ovine fibroblasts in a sacrificial fibrin gel were implanted into the left pulmonary branch of 3-month old lambs for 3, 6, and 18 months. A control group of Propaten® PTFE grafts was implanted for 6 months. Results The engineered grafts exhibit extensive site-appropriate recellularization after only 3 months and near-normal increase of diameter from the preimplant value of 6 mm to 12.9 mm and also a doubling of length from 6.0 mm to 13.0 mm at 6 months (n = 3) associated with apparent somatic graft growth (collagen content increase of 265% over 18-month, n = 2), along with excellent hemodynamics and no calcification, in contrast to the Propaten® grafts. The left-right flow distribution is nearly 50–50 for the engineered grafts at 6 months (n = 3) compared to about 20–80 for the Propaten® grafts (n = 3), which have less than one-half the diameter, a 6-fold higher pressure gradient, and stunted vascular development downstream of the graft. The engineered grafts exhibit a stable diameter over months 12–18 when the lambs become adult sheep (n = 2). Conclusions This study supports the use of these regenerative grafts with somatic growth capacity for clinical trial in patients born with a unilateral absent pulmonary artery branch, and it shows their potential for improving development of the downstream pulmonary vasculature.

1 January 2025 in Journal of the Heart Valve Society
Verified
Journal Article
Open access
MMMariah McMahon
Mariah McMahon
APAbrielle Prunty
Abrielle Prunty
JBJacob Benkofske
Jacob Benkofske
JBJames Berry
James Berry
RKRika Kawakami
Rika Kawakami
ZSZeeshan Syedain
Zeeshan Syedain
Congenital valve disease, predominantly in the pulmonary position, requires multiple replacements as current bioprosthetic valves degrade and calcify over time. An allogenic, decellularized bioengineered tissue with minimum immune response and calcification would provide an ideal solution for young patients and could substantially improve the standard of care. In this study, a transcatheter pulmonary valve with bioengineered tissue leaflets on a self-expanding nitinol stent was implanted for up to 18 months in five juvenile sheep using an 18Fr transapical delivery system. Serial echo monitoring showed an increase in cardiac output as the juvenile sheep grew without any decrease in effective orifice area (>2 cm 2 ) or increase in pressure gradients (<10 mmHg for both peak and mean). No valvular regurgitation, leaflet thickening, or tissue abnormality was reported at any time points. Micro-CT and histological assessment showed mild calcification and mild thrombosis. The 18-month implants in the highly calcific juvenile sheep model showed no loss of function and no deterioration of the bioengineered tissue, suggesting a suitable alternative leaflet material for younger patients where functional longevity is critical.